Breast cancer is now classified according to molecular factors that predict response to treatment, such as endocrine therapy to Luminal diseases, trastuzumab to HER2 positive diseases and chemotherapy to triple negative diseases, [4]and each intrinsic subtype has a unique risk of recurrence and death overtime.[5]The particular patterns of relapse and death differed according to these factors, and these patterns notably persisted with current therapies and improved over the last decades. The gene discussed is ERBB2; the disease is breast carcinoma.